99mtc-tetrofosmin scintigraphy in musculoskeletal tumours: the relationship between p-glycoprotein expression and tetrofosmin uptake in malignant lesions

Nuclear Medicine Communications

Volumn 23, Issue 10, 2002, Pages 991-1000

  Yapar, Z ^a   Kibar, M ^b   Ozbarlas, S ^b   Yapar, A F ^b   Uguz, A ^b   Zorludemir, S ^b   Herdem, M ^b  

^a ADANA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

99mTc tetrofosmin; Musculoskeletal tumours; P glycoprotein

Indexed keywords

GLYCOPROTEIN P; MEDRONATE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANEURYSMAL BONE CYST; ARTICLE; BONE CYST; BONE SCINTISCANNING; BREAST CARCINOMA; CHILD; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; EWING SARCOMA; FEMALE; FIBROSARCOMA; HEMANGIOMA; HETEROTOPIC OSSIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LYMPHOMA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MUSCULOSKELETAL DISEASE; MYXOSARCOMA; NEUROECTODERM TUMOR; NEUROFIBROMA; NONHODGKIN LYMPHOMA; OSSIFYING FIBROMA; OSTEOSARCOMA; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SYNOVIAL SARCOMA; TRANSITIONAL CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; BIOSYNTHESIS; BLOOD FLOW; BONE TUMOR; CLINICAL TRIAL; IMAGE PROCESSING; INFANT; METABOLISM; MIDDLE AGED; MUSCLE TUMOR; PREDICTION AND FORECASTING; PRESCHOOL CHILD; REPRODUCIBILITY; SCINTISCANNING; SOFT TISSUE TUMOR; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; SOFT TISSUE NEOPLASMS;

EID: 0036795704     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200210000-00009     Document Type: Article

References (30)

1. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MRI imaging in the local staging of primary malignant musculoskeletal neoplasms: report of the radiology diagnostic oncology group. Radiology 1997; 202: 237-246.
2. Boomsma MM, Niemeyer MG, van der Wall EE, et al. Tc-99m tetrofosmin myocardial SPECT perfusion imaging: comparison of rest-stress and stress-rest protocols. Int J Card Imaging 1998; 14: 105-111.
3. Grouters RG, Verzijlbergen JF, Muller AJ, et al. Prognostic value and quality of life in patients with normal rest thallium-201/stress technetium 99m-tetrofosmin dual-isotope myocardial SPECT. J Nucl Cardiol 2000; 7: 333-341.
4. Kostakoglu L, Uysal U, Özyar E, et al. A comparative study of technetium-99m sestamibi and technetium-99m tetrofosmin single-photon emission tomography in the detection of nasopharyngeal carcinoma. Eur J Nucl Med 1997; 24: 621-628.
5. Obwegeser R, Berghammer P, Rodrigues M, et al. A head-to-head comparison between technetium-99m-tetrofosmin and technetium-99m-MIBI scintigraphy to evaluate suspicious breast lesions. Eur J Nucl Med 1999; 26: 1553-1559.
6. Takekawa H, Shinano H, Tsukamoto E, et al. Technetium-99m-tetrofosmin imaging of lung cancer: relationship with histopathology. Ann Nucl Med 1999; 13: 71-75.
7. Hashimoto T, Takahashi K, Goto M, et al. Detection of malignant thymoma in primary tumour and metastatic lesions using 99mTc-tetrofosmin scintigraphy. Radiotech Med 2001; 19: 169-172.
8. 99mTc-tetrofosmin. Nucl Med Commun 1999; 20: 353-359.
9. Soderlund V, Jonsson C, Bauer HCF, et al. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 1997; 38: 682-686.
10. Soricelli A, Cuocolo A, Varrone A, et al. Technetium-99m-tetrofosmin uptake in brain tumours by SPECT: comparison with thallium-201 imaging. J Nucl Med 1998; 39: 802-806.
11. Ballinger JR, Bannerman J, Boxen I, et al. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumour cells. J Nucl Med 1996; 37: 1578-1582.
12. Perek N, Prevot N, Koumanov F, et al. Involvement of the glutathione S-conjugate compounds and the MRP protein in Tc-99m-tetrofosmin and Tc-99m-sestamibi uptake in glioma cell lines. Nucl Med Biol 2000; 27: 299-307.
13. Muzzammil T, Moore MJ, Ballinger JR. In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumours. Cancer Biother Radiopharm 2000; 15: 339-346.
14. Utsunomiya K, Ballinger JR, Piquette-Miller M, et al. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line. Eur J Nucl Med 2000; 27: 1786-1792.
15. Arbab AS, Koizumi K, Toyama K, et al. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumour cell lines. J Nucl Med 1996; 37: 1551-1556.
16. 99mTc-Q12 into human breast cancer cell lines. Eur J Nucl Med 1996; 23: 1361-1366.
17. 99mTc-medronate incorporation. Anticancer Res 1999; 19: 255-260.
18. Focacci C, Lattanzi R, Iadeluca ML, et al. Nuclear medicine in primary bone tumours. Eur J Radiol 1998; 27: 355-363.
19. Tryciecky EW, Gootschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MRI using the bone scan as a model. Semin Nucl Med 1997; 27: 142-151.
20. Abdel-Dayem HM. The role of nuclear medicine in primary bone and soft tissue tumours. Semin Nucl Med 1997; 27: 355-363.
21. Rigo P, Paulus P, Kaschten BJ, et al. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1642-1675.
22. Caner B, Kitapci M, Unlu M, et al. Technetium-99m-MIBI uptake in benign and malignant bone lesions: a comparative study with technetium-99m-MDP. J Nucl Med 1992; 33: 319-324.
23. Caluser CL, Abdel-Dayam HM, Macapinlac HA, et al. The value of thallium and three phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 1994; 21: 1198-1205.
24. 99mTc-furifosmin uptake in human soft tissue sarcoma cell lines. Eur J Nucl Med 2000; 27: 1839-1843.
25. Söderlund V, Jonsson C, Bauer HCF, et al. Comparison of technetium-99m-MIBI and technetium-99m-tetrofosmin uptake by musculoskeletal sarcomas. J Nucl Med 1997; 38: 682-686.
26. 99mTc-MIBI scintigraphy in musculoskeletal tumors. J Nucl Med 2001; 42: 33-37.
27. Shiau YC, Tsai SC, Wang JJ, et al. Predicting chemotherapy and comparing with P-glycoprotein expression using technetium-99m tetrofosmin scan in untreated malignant lymphomas. Cancer Lett 2001; 170: 139-146.
28. Kostakoglu L, Elahi N, Kiratli P, et al. Clinical validation of influence of Pgp on the uptake of Tc-99m-sestamibi in patients with malignant tumours. J Nucl Med 1997; 38: 1003-1008.
29. Kostakoglu L, Kiratli P, Ruacan S, et al. Association of tumour wash-out rates and accumulation of Tc-99m-MIBI with the expression of Pgp in lung cancer. J Nucl Med 1998; 39: 228-234.
30. Kostakoglu L. Multidrug resistance. Part B: other tumours. In: Khalkhali I, Maublant JC, Goldsmith SJ, eds. Nuclear oncology - diagnosis and therapy. Philadelphia: Lippincott Williams & Wilkins, 2001: 73-82.